A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.

Yasmine Fahfouhi¹, Stéphane Fiévez², Robert Cohen³, Corinne Levy³, Marta C Nunes⁴, Louis Chillotti⁵, Romain Moreau⁵, William Greenwood², Emmanuelle Blanc², Amy Law⁶

¹Pfizer France SAS, Paris, France. Electronic address: yasmine.fahfouhi@pfizer.com.

²Pfizer France SAS, Paris, France.

³ACTIV-Association Clinique et Thérapeutique Infantile du Val de Marne, Créteil, France; Infectiology Centre Hospitalier Intercommunal de Créteil, Créteil, France.

⁴Center of Excellence in Respiratory Pathogens, Hospices Civils de Lyon, Lyon, France.

⁵Stève Consultants, A Cytel Company, Paris, France.

⁶Pfizer Inc, New York, USA.

PubMed DOI

Abstract

OBJECTIVES: Most of the clinical and economic burden of the respiratory syncytial virus (RSV) in pediatric populations is concentrated among infants aged <1 year. Since 2024, RSVpreF vaccine is available in France for the vaccination of pregnant women between 32 and 36 weeks of gestational age, from September to January. This study aimed to model the impact of alternative RSVpreF national vaccinat…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.